TNON — Tenon Medical, Inc.

Summary of Tenon Medical (TNON) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Achieved record revenue of $1,200,000, a 32% increase from $900,000 in Q3 2024. Year-to-date revenue for the first nine months remained stable at $2,500,000 compared to the same period last year.
• Gross Profit: $800,000, representing a gross margin of 66%, up from 47% in the prior year quarter.
• Operating Expenses: Increased to $4,200,000 from $3,600,000 year-over-year, driven by higher sales commissions and integration costs related to the SciVantage acquisition.
• Net Loss: Reported a net loss of $3,300,000 ($0.40 per share), slightly higher than the loss of $3,200,000 in Q3 2024.
• Cash Position: Ended the quarter with $3,400,000 in cash and no debt. Subsequent to the quarter, raised an additional $2,850,000 through PIPE financing.

2. Strategic Updates and Business Highlights

• Acquisition: Completed the acquisition of CyVantage’s Symmetry and Symmetry Plus sacroiliac joint fusion technologies, enhancing Tenon’s product portfolio and market reach.
• Product Launches: Launched the Catamaran SE SI joint fusion system, which has seen over 1,000 implants and demonstrated strong clinical performance.
• Clinical Validation: Published peer-reviewed data supporting the efficacy of the Catamaran system, showing significant improvements in patient outcomes.
• Regulatory Milestone: Received FDA 510(k) clearance for the Symmetry Plus SI joint fusion system, which will be alpha launched soon.

3. Forward Guidance and Outlook

• Management is optimistic about continued revenue growth, particularly from the Catamaran system and the upcoming contributions from the Symmetry Plus system.
• Plans to expand the sales team and enhance commercial operations through a hybrid structure involving independent distributors.
• Anticipates that the integration of CyVantage will continue to yield positive results, with a focus on deepening market penetration and physician engagement.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: Despite revenue growth, the company continues to report significant net losses, which may raise concerns about long-term profitability.
• Integration Risks: While integration of CyVantage is progressing well, challenges remain in fully merging operations and ensuring smooth commercial execution.
• Market Competition: The company faces competitive pressures in the sacroiliac joint fusion market, which could impact growth and market share.

5. Notable Q&A Insights

• Revenue Breakdown: Approximately $1 million of Q3 revenue was attributed to Catamaran procedures, with early contributions from the Symmetry system noted.
• Growth Expectations: Management expects sequential growth in Catamaran procedures in Q4 2025, driven by clinical data and physician engagement.
• Alpha Launch Strategy: The Symmetry Plus launch will be a pilot with select physicians to gather feedback before a broader rollout.
• Integration Progress: The integration of CyVantage is largely complete, with a focus on aligning commercial strategies and enhancing sales capabilities.
• Payer Coverage: Emphasized the importance of clinical data in discussions with private payers to secure coverage for their technologies, indicating a parallel focus on commercial and clinical initiatives.

Overall, Tenon Medical is experiencing significant momentum in revenue growth and product development, but it continues to navigate challenges related to profitability and market competition.